Biotechnology companies like Fulcrum Therapeutics frequently adjust their staffing levels and execute targeted workforce reductions or operational restructuring phases following pipeline discontinuations, strategic reviews, or shifts in corporate focus. When the company halted its lead drug development program and initiated a comprehensive evaluation of strategic alternatives that ultimately culminated in its merger agreement with Slate Medicines, management took steps to realign operational expenses and personnel resources to match the streamlined pipeline priorities of the combined enterprise.